Trials / Unknown
UnknownNCT05190484
bIosimilar of aDalimumab, an European evAluation
An International, Prospective, Observational Study of Patients With Chronic Inflammatory Diseases, to Assess 12-months Persistence Drivers After Switching to an Adalimumab Biosimilar, Idacio®, in a Real World Setting
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,050 (estimated)
- Sponsor
- Fresenius Kabi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory diseases who were switched to FK adalimumab, in order to develop a model to predict persistence at 12 months.
Conditions
Timeline
- Start date
- 2022-04-30
- Primary completion
- 2023-04-30
- Completion
- 2024-04-30
- First posted
- 2022-01-13
- Last updated
- 2022-01-13
Source: ClinicalTrials.gov record NCT05190484. Inclusion in this directory is not an endorsement.